GHRP-2

Volume Pricing

Price per pack (10 vials). Discount applies to this compound only – no mix and match.

GHRP-2 — GHS-R1a Agonist / Synthetic Growth Hormone Secretagogue

GHRP-2 (Growth Hormone-Releasing Peptide-2), also known by its clinical name pralmorelin, is a synthetic hexapeptide that acts as a potent agonist of the ghrelin receptor (GHS-R1a). First developed and extensively characterized by Dr. Cyril Bowers and colleagues at Tulane University, GHRP-2 has since become one of the most widely studied growth hormone secretagogues in both preclinical and clinical research settings. Its primary mechanism — mimicking the endogenous hunger and GH-release signal of ghrelin — produces rapid, pulsatile increases in circulating growth hormone that closely mirror the body’s natural secretion patterns. This physiological fidelity, combined with its well-characterized receptor pharmacology, makes GHRP-2 a foundational tool in GH axis research.

Why GHRP-2’s Mechanism Is Distinctive

Most exogenous GH research involves direct hormone administration, which bypasses endogenous pituitary regulation entirely. GHRP-2 operates upstream — it engages the ghrelin receptor to stimulate the pituitary’s own somatotroph cells, preserving the natural feedback architecture of the GH axis. This makes it particularly valuable for studying the neuroendocrine regulation of growth hormone rather than simply its downstream effects.

GHRP-2 primarily stimulates GH release through cAMP production, which distinguishes it mechanistically from GHRP-6 (which acts primarily via intracellular calcium). This difference in second-messenger pathway has meaningful implications for comparative secretagogue research.

Research Applications

GHRP-2 is used in studies examining:

• Pulsatile GH secretion dynamics and GHS-R1a pharmacology
• Comparative efficacy among GH secretagogues (GHRP-2 vs. GHRP-6, ipamorelin, hexarelin)
• GHRH and ghrelin receptor synergy in amplified GH release protocols
• GH/IGF-1 axis modulation in aging, sarcopenia, and metabolic models
• Appetite and orexigenic pathway research via ghrelin receptor agonism
• HPA axis interactions — ACTH and cortisol co-secretion dynamics
• Diagnostic stimulation testing for hypothalamic-pituitary GH deficiency
• Body composition endpoints in GH-deficiency and hypogonadal models
• Sleep architecture and nocturnal GH secretion studies

Specifications

Reconstitution

GHRP-2 arrives as lyophilized powder and must be reconstituted with bacteriostatic water prior to use. Use the formula:

Total mg ÷ Volume added (mL) = Concentration (mg/mL)

Example (5mg vial): 5mg + 3mL BAC water = ~1.67mg/mL solution Example (10mg vial): 10mg + 3mL BAC water = ~3.33mg/mL solution

Reconstituted peptide should be stored at 2–8°C and used within 28–30 days. Do not freeze reconstituted solution. Administration on an empty stomach (30–60 minutes fasted) is standard practice in research protocols, as elevated plasma glucose and free fatty acids are known to blunt GH release in response to secretagogue stimulation.

Protocol Notes

GHRP-2 is active at microgram doses and produces its strongest GH pulse when administered in alignment with the body’s natural nocturnal secretion window. Timing administration to coincide with fasted states and sleep onset is the most common framework in research protocols.

Typical research dosing framework:

• Starting dose: 100mcg per administration
• Escalation: Increase by 50mcg every 1–2 weeks as tolerated; target range 100–300mcg
• Frequency: Once to twice daily (subcutaneous); bedtime dosing most common for GH pulse alignment; morning fasted dosing used in two-injection protocols
• Study duration: 8–12 weeks; longer protocols (up to 6 months) used in aging and body composition research
• Note: When used in combination with a GHRH analog (e.g., CJC-1295, sermorelin), GHRP-2 doses are typically maintained at the lower end of the range due to synergistic amplification of GH output

Commonly observed effects in research models:

• Appetite / GI: Marked increase in appetite within 20–30 minutes of administration (receptor-mediated, consistent and predictable); increased GI motility; flushing and sweating in some subjects
• Endocrine: Transient cortisol and ACTH elevation at higher doses; water retention and mild edema common in early protocol weeks; reduced insulin sensitivity and transient blood glucose elevation at elevated doses
• Other: Fatigue or somnolence post-injection (supports bedtime dosing); injection site redness or discomfort; numbness or tingling in extremities; arthralgias with prolonged use — incidence generally lower than observed with direct exogenous GH administration due to endogenous synthesis limits

Research Stacks

GHRP-2 is commonly paired in research settings with:

• GHRP-6 — GHRP-6 and GHRP-2 are both first-generation ghrelin receptor agonists with overlapping but distinct receptor binding affinities and side-effect profiles; researchers pair them to compare GHSR-1a agonism potency under controlled conditions.
• Ipamorelin — Ipamorelin is a selective GHSR agonist that does not significantly elevate cortisol or prolactin; it is studied alongside GHRP-2 to characterize selectivity differences between ghrelin receptor agonists with different off-target profiles.
• CJC-1295 No DAC — CJC-1295 No DAC stimulates somatotrophs via the GHRH receptor; pairing it with GHRP-2 creates dual-receptor GH stimulation, which is among the most studied combinations in GH secretagogue research.

Purity Guarantee

Every batch is ≥99% purity. If you independently test your compound and the results don’t match — send us the COA and we’ll issue store credit, no questions asked.